Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has complicated the management of inflammatory bowel diseases (IBD). Objectives: This study aimed to assess efficacy different anti-SARS-CoV-2 vaccines under treatments in IBD patients and identify predictive factors associated with lower serological response, including anti-tumor necrosis factor (anti-TNF) drug levels. Design: A prospective, double-center was conducted following messenger ribonucleotide acid (mRNA) non-mRNA vaccination. Methods: Healthy control (HC) were enrolled reduce bias. Baseline samples obtained 14 days after second dose impact conventional biological treatments. Clinical biochemical activity, response level, anti-TNF levels measured. Results: included 199 (mean age, 40.9 ± 12.72 years) 77 HC participants 50.3 12.36 years). Most (76.9%) all HCs received mRNA vaccines. Half on treatment (anti-TNF 68.7%). Biological thiopurine combined immunomodulation ( p < 0.001), vaccination promoted better antibody 0.001). Higher adalimumab caused = 0.006). W8 persistence level equal groups. Vaccination did not aggravate clinical disease activity 0.65). Conclusion: Anti-SARS-CoV-2 is considerably efficacious patients, promoting negative treatment, especially high levels, should be considered. Although midterm durability encouraging, more data are needed expand existing understanding this issue.